Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells

Leuk Res. 1995 Jan;19(1):7-13. doi: 10.1016/0145-2126(94)00118-t.

Abstract

In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily demonstrated after 1 h of exposure, reaching a maximal inhibitory effect at 96 h. Normal BM cells differed in their clonogenic response: short-term exposure to bryostatin-5 resulted in increased clonogenicity while longstanding exposure to bryostatin-5 permitted the survival of a substantial fraction of committed progenitors. This differential modulation of normal and leukemic myeloid clonogenicity by bryostatin-5 suggests a possible role for bryostatin-5 in the treatment of acute myeloid leukemia.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Bone Marrow / drug effects
  • Bone Marrow Cells
  • Bryostatins
  • Cell Division / drug effects
  • Cell Survival / drug effects
  • Hematopoiesis / drug effects*
  • Humans
  • Lactones / pharmacology*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / pathology
  • Macrolides
  • Stimulation, Chemical
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Bryostatins
  • Lactones
  • Macrolides
  • bryostatin 5